Authors
Haneen A Al-Mazroua, Hussain N Alhamami, Ahmed Nadeem, Mushtaq A Ansari, Saleh A Bakheet, Sabry M Attia, Wedad S Sarawi, Hatun A Alomar, Abdulaziz M S Alsaad, Ali A Alshamrani, Sheikh F Ahmad
Published in
Immunopharmacology and immunotoxicology. Pages 1-14. Aug 24, 2026. Epub Aug 24, 2026.
Abstract
Multiple sclerosis (MS) is an inflammatory, demyelinating, and neurodegenerative disease of the central nervous system (CNS) driven by autoimmune mechanisms. However, growing evidence indicates that B lymphocytes may contribute to the disease through antigen presentation and the production of proinflammatory mediators. This study aimed to examine the effect of JNJ 10191584 (JNJ), a potent and selective H4R antagonist, on the progression of EAE and to uncover the underlying mechanisms. The research explored the potential impact of H4R antagonists on inflammatory responses in B cells within an EAE mouse model of MS. EAE mice received an oral dose of JNJ at 6 mg/kg daily, starting on day 10 and continuing until day 42. Flow cytometry assessed JNJ's effect on the expression of NF-κB p65, IκBα, Notch1, Notch3, IL-2, IL-6, GM-CSF, iNOS, TNF-α, and MCP-1 in CD19+ B cells. RT-PCR was used to evaluate the impact of JNJ on mRNA levels of these inflammatory markers in brain tissue. In EAE mice, JNJ treatment reduced the number of CD19+ cells expressing NF-κB p65, IκBα, Notch1, Notch3, IL-2, IL-6, GM-CSF, iNOS, and MCP-1. Additionally, JNJ decreased mRNA expression of inflammatory markers in brain tissue compared with vehicle-treated mice. These results suggest that targeting H4R with antagonists could offer a new therapeutic approach for MS by specifically modulating B-cell-mediated inflammation.
PMID:
42634537
Bibliographic data and abstract were imported from PubMed on 24 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0